Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721

LD50 studies and 35S-WR-2721 biodistribution

J. S. Rasey, N. J. Nelson, P. Mahler, K. Anderson, Kenneth Krohn, T. Menard

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

The ability of WR-2721 to protect mice against two modes of death following whole-body radiation with 137Cs γ rays or d(22)+Be neutrons was examined. For single fractions, 400 mg/kg WR-2721 was administered prior to irradiation. In two-fraction exposures, the dose was 275 mg/kg given prior to each fraction. Dose modification factors (DMFs) were calculated as ratios of LD50 values. For single fractions of γ rays, the DMF was 1.74 for the LD(50/7) end point and for LD(50/30), the DMF for single fractions was 2.25. For two fractions 3 hr apart, it was 1.88. For single fractions of cyclotron neutrons, the DMF was 1.32 for LD(50/7). Measured with the LD(50/30) end point, the DMF for single neutrons doses was 1.41 and for two fractions, 1.19. Substantial radioprotection of bone marrow and intestinal epithelium against cyclotron neutrons was seen in these investigations. Biodistribution studies were done following ip injection of 35S-labeled WR-2721 into C3H mice bearing RIF-1 tumors. Blood levels peaked at 10 min after injection and declined thereafter. Most normal tissues achieved maximum levels of 35S at 30 to 60 min postinjection and high concentrations were retained in most tissues for up to 2 hr. Assuming that all 35S is in parent compound or dephosphorylated radioprotective metabolites, the concentration of protector (milligram per gram tissue) in various organs at 30 min postinjection ranked as follows: kidney > submandibular gland ≥ liver = lung > gut > heart ≥ blood > skin > tumor > brain. High levels of 35S were achieved and retention times were long in certain normal tissues which respond at early or late times postirradiation and may be dose limiting in radiotherapy: kidney, liver, salivary gland, and lung. These combined observations suggest that there is potential for protecting dose-limiting, late-responding normal tissue in the radiotherapy of human cancer with both neutrons and conventional radiotherapy.

Original languageEnglish (US)
Pages (from-to)598-607
Number of pages10
JournalRadiation Research
Volume97
Issue number3
StatePublished - 1984
Externally publishedYes

Fingerprint

Amifostine
Cyclotrons
Lethal Dose 50
Gamma Rays
Neutrons
lethal dose 50
gamma radiation
cyclotrons
gamma rays
neutrons
dosage
Radiotherapy
radiotherapy
radiation therapy
Kidney
Neoplasms
Lung
Injections
kidneys
Inbred C3H Mouse

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Radiology Nuclear Medicine and imaging
  • Biophysics
  • Radiation

Cite this

Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721 : LD50 studies and 35S-WR-2721 biodistribution. / Rasey, J. S.; Nelson, N. J.; Mahler, P.; Anderson, K.; Krohn, Kenneth; Menard, T.

In: Radiation Research, Vol. 97, No. 3, 1984, p. 598-607.

Research output: Contribution to journalArticle

Rasey, J. S. ; Nelson, N. J. ; Mahler, P. ; Anderson, K. ; Krohn, Kenneth ; Menard, T. / Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721 : LD50 studies and 35S-WR-2721 biodistribution. In: Radiation Research. 1984 ; Vol. 97, No. 3. pp. 598-607.
@article{5e529646cfa44512a18470f92f9892dd,
title = "Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution",
abstract = "The ability of WR-2721 to protect mice against two modes of death following whole-body radiation with 137Cs γ rays or d(22)+Be neutrons was examined. For single fractions, 400 mg/kg WR-2721 was administered prior to irradiation. In two-fraction exposures, the dose was 275 mg/kg given prior to each fraction. Dose modification factors (DMFs) were calculated as ratios of LD50 values. For single fractions of γ rays, the DMF was 1.74 for the LD(50/7) end point and for LD(50/30), the DMF for single fractions was 2.25. For two fractions 3 hr apart, it was 1.88. For single fractions of cyclotron neutrons, the DMF was 1.32 for LD(50/7). Measured with the LD(50/30) end point, the DMF for single neutrons doses was 1.41 and for two fractions, 1.19. Substantial radioprotection of bone marrow and intestinal epithelium against cyclotron neutrons was seen in these investigations. Biodistribution studies were done following ip injection of 35S-labeled WR-2721 into C3H mice bearing RIF-1 tumors. Blood levels peaked at 10 min after injection and declined thereafter. Most normal tissues achieved maximum levels of 35S at 30 to 60 min postinjection and high concentrations were retained in most tissues for up to 2 hr. Assuming that all 35S is in parent compound or dephosphorylated radioprotective metabolites, the concentration of protector (milligram per gram tissue) in various organs at 30 min postinjection ranked as follows: kidney > submandibular gland ≥ liver = lung > gut > heart ≥ blood > skin > tumor > brain. High levels of 35S were achieved and retention times were long in certain normal tissues which respond at early or late times postirradiation and may be dose limiting in radiotherapy: kidney, liver, salivary gland, and lung. These combined observations suggest that there is potential for protecting dose-limiting, late-responding normal tissue in the radiotherapy of human cancer with both neutrons and conventional radiotherapy.",
author = "Rasey, {J. S.} and Nelson, {N. J.} and P. Mahler and K. Anderson and Kenneth Krohn and T. Menard",
year = "1984",
language = "English (US)",
volume = "97",
pages = "598--607",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "3",

}

TY - JOUR

T1 - Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721

T2 - LD50 studies and 35S-WR-2721 biodistribution

AU - Rasey, J. S.

AU - Nelson, N. J.

AU - Mahler, P.

AU - Anderson, K.

AU - Krohn, Kenneth

AU - Menard, T.

PY - 1984

Y1 - 1984

N2 - The ability of WR-2721 to protect mice against two modes of death following whole-body radiation with 137Cs γ rays or d(22)+Be neutrons was examined. For single fractions, 400 mg/kg WR-2721 was administered prior to irradiation. In two-fraction exposures, the dose was 275 mg/kg given prior to each fraction. Dose modification factors (DMFs) were calculated as ratios of LD50 values. For single fractions of γ rays, the DMF was 1.74 for the LD(50/7) end point and for LD(50/30), the DMF for single fractions was 2.25. For two fractions 3 hr apart, it was 1.88. For single fractions of cyclotron neutrons, the DMF was 1.32 for LD(50/7). Measured with the LD(50/30) end point, the DMF for single neutrons doses was 1.41 and for two fractions, 1.19. Substantial radioprotection of bone marrow and intestinal epithelium against cyclotron neutrons was seen in these investigations. Biodistribution studies were done following ip injection of 35S-labeled WR-2721 into C3H mice bearing RIF-1 tumors. Blood levels peaked at 10 min after injection and declined thereafter. Most normal tissues achieved maximum levels of 35S at 30 to 60 min postinjection and high concentrations were retained in most tissues for up to 2 hr. Assuming that all 35S is in parent compound or dephosphorylated radioprotective metabolites, the concentration of protector (milligram per gram tissue) in various organs at 30 min postinjection ranked as follows: kidney > submandibular gland ≥ liver = lung > gut > heart ≥ blood > skin > tumor > brain. High levels of 35S were achieved and retention times were long in certain normal tissues which respond at early or late times postirradiation and may be dose limiting in radiotherapy: kidney, liver, salivary gland, and lung. These combined observations suggest that there is potential for protecting dose-limiting, late-responding normal tissue in the radiotherapy of human cancer with both neutrons and conventional radiotherapy.

AB - The ability of WR-2721 to protect mice against two modes of death following whole-body radiation with 137Cs γ rays or d(22)+Be neutrons was examined. For single fractions, 400 mg/kg WR-2721 was administered prior to irradiation. In two-fraction exposures, the dose was 275 mg/kg given prior to each fraction. Dose modification factors (DMFs) were calculated as ratios of LD50 values. For single fractions of γ rays, the DMF was 1.74 for the LD(50/7) end point and for LD(50/30), the DMF for single fractions was 2.25. For two fractions 3 hr apart, it was 1.88. For single fractions of cyclotron neutrons, the DMF was 1.32 for LD(50/7). Measured with the LD(50/30) end point, the DMF for single neutrons doses was 1.41 and for two fractions, 1.19. Substantial radioprotection of bone marrow and intestinal epithelium against cyclotron neutrons was seen in these investigations. Biodistribution studies were done following ip injection of 35S-labeled WR-2721 into C3H mice bearing RIF-1 tumors. Blood levels peaked at 10 min after injection and declined thereafter. Most normal tissues achieved maximum levels of 35S at 30 to 60 min postinjection and high concentrations were retained in most tissues for up to 2 hr. Assuming that all 35S is in parent compound or dephosphorylated radioprotective metabolites, the concentration of protector (milligram per gram tissue) in various organs at 30 min postinjection ranked as follows: kidney > submandibular gland ≥ liver = lung > gut > heart ≥ blood > skin > tumor > brain. High levels of 35S were achieved and retention times were long in certain normal tissues which respond at early or late times postirradiation and may be dose limiting in radiotherapy: kidney, liver, salivary gland, and lung. These combined observations suggest that there is potential for protecting dose-limiting, late-responding normal tissue in the radiotherapy of human cancer with both neutrons and conventional radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0021173683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021173683&partnerID=8YFLogxK

M3 - Article

VL - 97

SP - 598

EP - 607

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 3

ER -